Cattle producers take pain relief by the horns
Tri-Solfen from Bayer now registered for use for dehorning and disbudding in calves
Cattle producers across Australia are now able to deliver better welfare outcomes for their herds with the recent registration of pain relief solution Tri-Solfen for use for dehorning and disbudding.
Previously registered for use following mulesing and tail docking in lambs, and castration of lambs and calves, the label extension allows cattle producers to put best practice solutions in place to benefit animal welfare.
“Producers want to be on the front-foot when it comes to effective pain relief. Previously, Tri-Solfen has been available for use for dehorning only under veterinary supervision. Dairy and beef cattle producers can now take charge of pain relief themselves and incorporate the use of Tri-Solfen into their animal husbandry procedures on farm,” said Andrew Mason, Head of Bayer Animal Health in Australia.
Tri-Solfen, available in Australia from Bayer Animal Health, is a gel spray formulation containing a combination of local anaesthetics, adrenaline and an antiseptic. It is applied as a one-off treatment to wound sites following mulesing, tail docking, castration and disbudding / dehorning. The unique formulation of Tri-Solfen offers quick and long lasting pain relief, reduces bleeding and facilitates wound healing, and is easy to apply.
Developed by Medical Ethics and first registered in 2012, Tri-Solfen has since been used to successfully treat over 80 million animals undergoing routine surgeries in the Australian livestock industries.
“The widespread adoption of pain relief measures across all areas of livestock production has been remarkable,” said Medical Ethics managing director Allan Giffard. “Australian producers have shown a serious commitment to animal welfare and are very willing to minimise pain and enhance wound healing.”
Peter Windsor, Professor Emeritus at the University of Sydney, played a key role in the research that was conducted to achieve the label extension. “The development and use of Tri-Solfen is crucial in advancing animal welfare in Australia and potentially globally. The recent broadening of the Tri-Solfen registration is an important step in diminishing concerns of producers and consumers on the adverse welfare outcomes of pain inflicted during interventions performed routinely in livestock husbandry," said Professor Windsor.
The registration for the use of Tri-Solfen following disbudding and dehorning has also been welcomed by peak industry body, Dairy Australia. Kathryn Davis, program leader for animal health and fertility with Dairy Australia said, "This is great news for dairy calf welfare. It is now easy for farmers and disbudding contractors to provide cheap and effective pain relief for calves after disbudding by heat cautery."
Mr Mason is confident that dairy and beef producers will be strong advocates for the quick and universal adoption of Tri-Solfen into their animal husbandry programs. “As a leader in animal health, Bayer is committed to applying its capabilities and influence to improve animal well-being by focussing on the key challenges where we can make a difference. Tri-Solfen is a critical advance in animal welfare that will play a key role in ensuring the future success of our livestock industries.”
About Bayer in Australia
Bayer is a global enterprise founded in Germany with core competencies in the Life Science fields of healthcare, agriculture and animal health. Its products and services are designed to benefit both people and animals, and improve their quality of life. It has operated in Australia since 1925 and has a long term commitment to the health of Australians. Locally, Bayer currently employs almost 900 people across the country and is dedicated to servicing the needs of rural Australia and the local community. Bayer is deeply committed to research and development and has a strong tradition of innovation. The company’s focus on people, partnerships and innovation underpins all aspects of its operations, consistent with its mission, Science for a better life.
Lachlan Bird, phone +61 407 885 209
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.